We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Sciences’ HIV Drug Shows Long-Term Promise in Late-Stage Trials
Gilead Sciences’ HIV Drug Shows Long-Term Promise in Late-Stage Trials
Gilead Sciences’ daily oral HIV blockbuster Biktarvy has shown success as a long-term treatment, demonstrating continued high efficacy and strong viral suppression in two phase 3 trials that conducted years of follow-up.